Skip to main content

Table 2 Factors contributing to Physical Summary Score (PhS) in 60 patients with new-onset polyarticular juvenile idiopathic arthritis

From: Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial

 

Univariate

Mixed Model

β (95% CI)/Mean PhS (95% CI)

p

β (95% CI)

p

Gender (mean)

 

0.14

  

 Female

44.5 (40.7 to 48.3)

   

 Male

39.9 (34.9 to 44.8)

   

Time of visit (weeks)a

 

<0.001

 

<0.001

0

26.22 (22.04 to 30.39)

 

35.46 (30.91 to 40.04)

 

6

33.53 (29.43 to 37.63)

 

38.38 (34.30 to 42.46)

 

12

38.69 (34.59 to 42.79)

 

39.95 (36.34 to 43.55)

 

24

47.98 (43.76 to 52.19)

 

43.57 (41.63 to 45.86)

 

36

48.07 (43.81 to 52.32)

 

44.62 (42.04 to 47.19)

 

48

49.80 (45.54 to 54.05)

 

44.29 (41.07 to 47.51)

 

54

51.66 (47.40 to 55.91)

 

46.51 (43.66 to 49.35)

 

Age at onset

-0.01 (-0.97 to 0.95)

0.98

  

Treatment (mean) b

 

0.043

 

0.419

IFX+ MTX

46.2 (41.0 to 50.5)

0.046c

40.19 (36.98 to 43.42)

 

Triple

45.5 (40.4 to 50.5)

0.065d

42.70 (39.85 to 45.55)

 

MTX

38.7 (33.5 to 43.9)

 

42.65 (39.53 to 45.78)

 

JADAS10

-1.258 (-1.45 to -1.06)

<0.001

-0.347(-0.72 to 0.024)

0.067

Pain-VAS

-0.432 (-0.49 to -0.38)

<0.001

-0.204 (-0.28 to -0.12)

<0.001

Corticosteroid usee

-0.473 (-0.64 to -0.30)

<0.001

-0.004 (-0.019 to 0.10)

0.554

Time in remissionf

0.204 (0.073 to 0.334)

0.003

0.172 (0.05 to 0.29)

0.005

CHAQ

-23.25 (-26.1 to -20.4)

<0.001

-11.2 (-15.8 to -6.67)

<0.001

CHAQ*JADAS

  

0.087 (-0.29 to 0.47)

0.658

  1. For numerical factors, Coefficient beta indicated; for categorical values mean PhS value indicated.
  2. Sidak correction for multiple comparisons used. Factors with p-value <0.05 in univariate analyses were selected for multivariate mixed model. Values shown in Mixed Model column have been adjusted with other variables in the model. IFX+MTX: infliximab plus methotrexate; Triple: methotrexate, hydroxychloroquine, and sulfasalazine; MTX methotrexate monotherapy, JADAS juvenile arthritis disease activity score, VAS visual analoque scale, CHAQ child health assessment questionnaire, PhS Physical summary Score. aValues present mean (95% CI) PhS in all patients at each time point bValues present mean (95%CI) PhS at all time points in each treatment group cIFX+MTX vs MTX; dTriple vs MTX; for IFX+MTX vs Triple p=0.84; eAmount of corticosteroids per body weight (intra-articular or oral) before individual study visit, adjusted for 6 weeks’ time (mg/kg); fCumulative time in remission since onset, *interaction term